Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma

被引：0
|
作者：
Patel, Kishan
Parker, Terri L.
Di, Mengyang
Bar, Noffar
Huntington, Scott F.
Giri, Smith
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141972
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM).
    Delimpasi, Sosana
    Pour, Ludek
    Auner, Holger W.
    Dimopoulos, Meletios A.
    Rappaport, Alon
    Fortin, Lisa
    Shah, Jatin J.
    Shacham, Sharon
    Kauffman, Michael G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
    Auner, Holger W.
    Gavriatopoulou, Maria
    Delimpasi, Sosana
    Simonova, Maryana
    Spicka, Ivan
    Pour, Ludek
    Dimopoulos, Meletios A.
    Kriachok, Iryna
    Pylypenko, Halyna
    Leleu, Xavier
    Doronin, Vadim
    Usenko, Ganna
    Hajek, Roman
    Benjamin, Reuben
    Dolai, Tuphan Kanti
    Sinha, Dinesh Kumar
    Venner, Christopher P.
    Garg, Mamta
    Stevens, Don Ambrose
    Quach, Hang
    Jagannath, Sundar
    Moreau, Phillipe
    Levy, Moshe
    Badros, Ashraf
    Anderson, Larry D., Jr.
    Bahlis, Nizar J.
    Facon, Thierry
    Victoria Mateos, Maria
    Cavo, Michele
    Chai, Yi
    Arazy, Melina
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    Richardson, Paul G.
    Grosicki, Sebastian
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (06) : 708 - 718
  • [23] Trial in Progress: Once-Weekly vs Twice-Weekly Dosing of Carfilzomib-Lenalidomide-Dexamethasone in Patients w/Relapsed or Refractory Multiple Myeloma
    Leleu, Xavier
    Beksac, Meral
    Mateos, Maria-Victoria
    Pour, Ludk
    Weisel, Katja
    Coriu, Daniel
    Obreja, Mihaela
    Goldrick, Amanda
    Dimopoulos, Meletios A.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S16 - S16
  • [24] A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly
    Leleu, Xavier
    Chari, Ajai
    Richard, Shambavi
    Khurana, Monica
    Yusuf, Akeem
    Usmani, Saad Z.
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (12) : 1049 - 1058
  • [25] Efficacy of Once-Weekly Bortezomib with Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma
    Gut, Natalia
    Yucebay, Filiz
    Dempsey, Jessica
    Li, Junan
    Benson, Don M., Jr.
    BLOOD, 2018, 132
  • [26] Trial in Progress: Once-Weekly vs Twice-Weekly Dosing of Carfilzomib-Lenalidomide-Dexamethasone in Patients w/Relapsed or Refractory Multiple Myeloma
    Leleu, Xavier
    Beksac, Meral
    Mateos, Maria-Victoria
    Pour, Ludek
    Weisel, Katja
    Coriu, Daniel
    Obreja, Mihaela
    Goldrick, Amanda
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E266 - E267
  • [27] Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma
    Totani, Haruhito
    Ri, Masaki
    Kato, Chie
    Nakashima, Takahiro
    Suzuki, Nana
    Hagiwara, Shinya
    Kanamori, Takashi
    Murakami, Satsuki
    Masuda, Arisa
    Kinoshita, Shiori
    Yoshida, Takashi
    Narita, Tomoko
    Ito, Asahi
    Kusumoto, Shigeru
    Ishida, Takashi
    Komatsu, Hirokazu
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (03) : 316 - 321
  • [28] Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma
    Haruhito Totani
    Masaki Ri
    Chie Kato
    Takahiro Nakashima
    Nana Suzuki
    Shinya Hagiwara
    Takashi Kanamori
    Satsuki Murakami
    Arisa Masuda
    Shiori Kinoshita
    Takashi Yoshida
    Tomoko Narita
    Asahi Ito
    Shigeru Kusumoto
    Takashi Ishida
    Hirokazu Komatsu
    Shinsuke Iida
    International Journal of Hematology, 2016, 103 : 316 - 321
  • [29] Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China
    Yao, Rongxin
    Hu, Xudong
    Zhou, Shuping
    Zhang, Qianying
    Huang, He
    Sun, Ni
    Guo, Wenjian
    Yu, Kang
    Lin, Ying
    MEDICINE, 2019, 98 (39)
  • [30] Efficacy and Safety of Bortezomib plus Dexamethasone Therapy for Refractory or Relapsed Multiple Myeloma: Once-weekly Administration of Bortezomib may Reduce the Incidence of Gastrointestinal Adverse Events
    Fukushima, Toshihiro
    Nakamura, Takuji
    Iwao, Haruka
    Nakajima, Akio
    Miki, Miyuki
    Sato, Tomomi
    Sakai, Tomoyuki
    Sawaki, Toshioki
    Fujita, Yoshimasa
    Tanaka, Masao
    Masaki, Yasufumi
    Nakajima, Hideo
    Motoo, Yoshiharu
    Umehara, Hisanori
    ANTICANCER RESEARCH, 2011, 31 (06) : 2297 - 2302
12345